SCHEMBL4719957

SCHEMBL4719957

COc1nc(C(F)(F)F)cc(C)c1C(=O)NC(CN1CCOCC1)C1CCC(S(=O)(=O)CC2CC2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 4/20 0.37
RAF1 P04049 7/20 0.34
BRAF P15056 7/20 0.34
PIK3CD O00329 3/20 0.34
HPGD P15428 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
F10 P00742 1/20 0.32
CCR1 P32246 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LCK P06239 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540933 0.94 HDAC4 (0.41) HDAC4F10CCR1
SCHEMBL3543136 0.82 CNR2 (0.32) HPGDKDM4EMEN1ALDH1A1KMT2A
SCHEMBL5918346 0.81 SLC6A9 (0.39) PIK3CDHPGDF10KDM4EMEN1
SCHEMBL4722312 0.81 HDAC4 (0.42) HDAC4HDAC6MEN1ALDH1A1TP53
SCHEMBL5918431 0.76 SLC6A9 (0.35) HPGDKDM4ETP53SMN1; SMN2NPSR1
SCHEMBL2054770 0.75 PDE2A (0.38)
SCHEMBL3537221 0.75 SLC6A9 (0.34)
SCHEMBL3537225 0.75 SLC6A9 (0.34)
SCHEMBL3540928 0.74 SLC6A9 (0.41)
SCHEMBL3543131 0.74 SLC6A9 (0.36) HPGDMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893566-B1 CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA MERCK SHARP & DOHME (GB) 2013-02-13 EP claimed
EP-1893566-A1 CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA MERCK SHARP & DOHME LTD. (GB) 2008-03-05 EP claimed
WO-2006131711-A1 CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA MERCK SHARP & DOHME LIMITED (GB) 2006-12-14 WO claimed
US-20060276655-A1 Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia MERCK SHARP & DOHME (UK) LIMITED (GB) 2006-12-07 US claimed
EP-1893566-B1 CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA MERCK SHARP & DOHME (GB) 2013-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276655-A1 Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia GLRA1, GNMT, MGAT1 HDAC4 2830/4885RAF1 2806/4885BRAF 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.